Portfolio company
Chromacure
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small molecule therapeutics for oncology patients to address unmet clinical needs in cancer treatment.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Akanocure Pharmaceuticals
This company develops small molecule drugs targeting orphan and unmet needs in oncology for healthcare providers and patients.
Scorpion Therapeutics
This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.
iOnctura
The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.
Crossfire Oncology
This company develops kinase-targeting inhibitors, degraders and degrader-antibody conjugates to treat cancer patients.
Accent Therapeutics
This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.